Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) [Yahoo! Finance]
Citius Oncology, Inc. (CTOR)
Company Research
Source: Yahoo! Finance
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. With the latest financial year loss of US$25m and a trailing-twelve-month loss of US$24m, the US$60m market-cap company alleviated its loss by moving closer towards its target of breakeven. As path to profitability is the topic on Citius Oncology's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. According to some industry analysts covering Citius Oncology, breakeven is near. They expect the company to post a final loss in 2026, before turning a profit of US$44m in 2027. Therefore, the company is expected to breakeven just over a year from today. How fast will the company have to grow each year in order to re
Show less
Read more
Impact Snapshot
Event Time:
CTOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTOR alerts
High impacting Citius Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CTOR
News
- Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical DevelopmentPR Newswire
- Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts [Yahoo! Finance]Yahoo! Finance
- Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma ExpertsPR Newswire
- Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers [Yahoo! Finance]Yahoo! Finance
- Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic CancersPR Newswire
CTOR
Sec Filings
- 3/31/26 - Form 8-K
- 3/10/26 - Form 8-K
- 3/4/26 - Form 8-K
- CTOR's page on the SEC website